Clinical Trial Detail

NCT ID NCT01814553
Title ADAM-Afatinib Diarrhea Assessment and Management
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Boehringer Ingelheim
Indications

lung adenocarcinoma

Therapies

Afatinib + Loperamide

Age Groups: adult

Additional content available in CKB BOOST